This resulted in a robust and sustained gp100-specific CD8+ T cell response independent of prior CMV infection and immunity, and immunization with MCMV-gp100KGP resulted in tumor rejection in both prophylactic and therapeutic settings [95]. Here, CD8A is linked to neoplasm.